Merck Drops $9.2 Billion to Snag Experimental Flu Drug — A Bold Bet Amid Keytruda Patent Cliff
Merck Makes Massive $9.2 Billion Move to Strengthen Flu Pipeline Merck has just made headlines with a blockbuster acquisition: the
Novartis CEO Signals Bold M&A Plans Following $12 Billion Avidity Biosciences Deal
Novartis is making waves in the pharmaceutical industry with its latest move to acquire Avidity Biosciences for approximately $12 billion,